A Phase 3 interventional study of MLC 901 and Placebo in Alzheimer's Disease Dementia, sponsored by Moleac Pte Ltd.. Not yet recruiting at 1 site in Singapore. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Moleac Pte Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Alzheimer Disease with a site in Singapore — 6 open to participants now, 10 under way, 4 of them phase 3. Alzheimer Disease · Singapore.
Among the 27 studies in Alzheimer Disease with a site in Singapore, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 in phase 3, and was the 25th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →6 of the 27 studies in Alzheimer Disease with a site in Singapore are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Singapore, United States, Australia and 1 more country
Ages 50–85
Merck Sharp & Dohme LLC · Sites in Singapore, United States, Argentina and 8 more countries
Ages 50–85
Eidos Therapeutics, a BridgeBio company · Sites in Singapore, United States, Argentina and 21 more countries
Ages 18–75
Vincent Tay Khwee Soon · Sites in Singapore
Ages 50–80
Eli Lilly and Company · Sites in Singapore
Ages 55–85
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 14 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 587 across the 25 interventional studies, 284 across the 2 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Moleac Pte Ltd. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Moleac Pte Ltd. has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Alzheimer Disease with a site in Singapore that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07598370Eli Lilly and CompanyA Study of LY3439539 in Participants With Alzheimer's Disease | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Alzheimer Disease with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects on plasma biomarkers compared to placebo.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatments that slow progression. Current symptomatic therapies provide modest benefit, while anti-amyloid agents target a single pathway and have uncertain long-term outcomes. Multitarget approaches may provide broader and more durable benefit. MLC901 (NeuroAiD™II), a Traditional Chinese Medicine derived formulation, has shown neuroprotective and neuroproliferative properties in preclinical studies through multimodal mechanisms, including modulation of amyloid beta and tau phosphorylation, reduction of oxidative stress and inflammation, and promotion of neurogenesis and synaptogenesis. Clinical studies, including the ATHENE trial, suggest MLC901 may slow cognitive decline and is well tolerated. ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolling approximately 350 patients with mild to moderate AD across Southeast Asia. Participants will receive MLC901 or placebo for 12 months. The primary objective is to determine whether MLC901 is superior to placebo in slowing cognitive decline as measured by ADAS-Cog11. Secondary and exploratory objectives include global cognition, function, behavior, safety, and plasma biomarkers of AD (p-tau217, NfL and GFAP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A second study partner may serve as backup. If the original study partner withdraws from participation, a replacement study partner may be permitted at the investigator's discretion. The replacement study partner must provide informed consent prior to their first study visit with the subject.
Exclusion Criteria:
The most recent available scan (obtained at diagnosis or subsequently) is usually sufficient for screening eligibility to exclude these other conditions. Repeat imaging may need in some cases to be considered if there is clinically significant deterioration or new neurological signs suggestive of a cerebrovascular event.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active arm
Drug: MLC 901
Matching placebo
Drug: Placebo
Oral capsule, 2 capsules 3 times a day for 12 months
Oral capsule, 2 capsules 3 times a day for 12 months
Alzheimer's Disease Assessment Scale-Cognitive Subscale11 (ADAS-Cog11)
The ADAS-Cog is a rater-administered instrument designed to assess the severity of cognitive impairment and associated non-cognitive behaviors characteristic of individuals with AD. It is the most widely used cognitive scale in clinical trials evaluating treatments for mild to moderate AD. For this study, the version of ADAS-Cog11 will be used as the primary efficacy assessment. The ADAS Cog11 consists of 11 items assessing key areas of cognitive function that are commonly impaired in AD, including: orientation, word recall, word recognition, remembering word recognition test instructions, commands, comprehension of spoken language, naming, word-finding difficulty, spoken language ability, construction praxis, and ideational praxis. The ADAS-Cog11 total score ranges from 0 to 70, with higher scores indicating greater cognitive impairment.
Time frame: Baseline, Month 6 and Month 12
Clinical Dementia Rating (CDR): Global Score and Sum of Boxes (CDR-SB)
The CDR evaluates both cognitive and functional domains through structured interviews conducted with both the participant and a knowledgeable informant (such as a caregiver or study partner). The assessment is administered by a trained assessor according to a standardized protocol. The CDR includes the following 6 domains: 3 cognitive domains (memory, orientation, and judgment/problem solving) and 3 functional domains (community activities, home and leisure, and personal care). Each domain is rated on a scale from 0 (no impairment) to 3 (severe impairment). The CDR yield 2 scores, including CDR Global Score and CDR-SB. The CDR global score: a categorical rating from 0 to 3, derived via a standardized algorithm. This score is used to stage the severity of dementia as follows: 0= No dementia; 0.5= Very mild dementia; 1= Mild dementia; 2= Moderate dementia; 3= Severe dementia. CDR-SB: a continuous score ranging from 0 to 18, calculated by summing the individual domain scores.
Time frame: Baseline, Month 6 and Month 12
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
The ADCS-ADL, developed by Galasko et al, is the most widely used instrument for assessing functional outcomes in patients with AD. This 23-item scale evaluates both basic activities of daily living-such as eating and toileting-and more complex instrumental activities of daily living. The ADCS-ADL is administered as a structured interview with the participant's study partner or caregiver. For each item, the study partner is first asked whether the participant attempted the activity within the past four weeks. If so, the study partner is then asked to describe the participant's performance, which is scored accordingly. The total ADCS-ADL score ranges from 0 to 78, with lower scores indicating greater functional impairment.
Time frame: Baseline, Month 6 and Month 12
Neuropsychiatric Inventory (NPI)
The NPI is a validated instrument developed to assess a broad spectrum of behavioral and psychological symptoms commonly observed in individuals with dementia. The purpose of the NPI is to characterize the presence and severity of these symptoms. The questionnaire assesses 12 neuropsychiatric symptom domains: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor behavior, nighttime disturbances, and appetite/eating abnormalities. For each symptom domain, both frequency and severity are assessed. Severity is rated on a 3-point scale (mild, moderate, or marked), while caregiver distress related to each symptom is also rated on a 6-point scale (ranging from no distress to very severe distress). The NPI is administered via a structured interview with the subject's study partner or caregiver, who provides observations based on the subject's behavior.
Time frame: Baseline, Month 6 and Month 12
Adverse events
Listing and calculating the number and percentage of subjects experiencing non-serious and serious adverse events for each arm.
Time frame: Up to 52 weeks
Plasma biomarkers - phosphorylated tau (p-tau217)
Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate p-tau217 in pg/mL.
Time frame: Baseline and Month 12
Plasma biomarkers - neurofilament light chain (NfL)
Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate NfL in pg/mL.
Time frame: Baseline and Month 12
Plasma biomarkers - glial fibrillary acidic protein (GFAP)
Plasma samples will be collected from all subjects and used for research purposes to identify dynamic biomarkers that may be predictive of treatment response to MLC901. During screening, at baseline and subsequent visits as detailed in the Schedule of Events, whole blood samples will be obtained from every subject who has consented to participate in the study. The plasma samples will be used to evaluate GFAP in pg/mL.
Time frame: Baseline and Month 12
Plan to share: No — There are no plans to share individual participant data (IPD) for this study. Only de-identified, aggregate study findings will be disseminated through scientific meetings and peer-reviewed publications.
Start is estimated for Aug 2026; primary completion for Feb 2029, 30 months later.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 30 months is below that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Neuroaid
Moleac Pte Ltd.